Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Baker Bros. Advisors Sells Some MEI Pharma, Discloses a Massive Stake in Mirati Therapeutics

In a couple 13D filings with the SEC, Julian and Felix Baker‘s Baker Bros. Advisors reported a 19.9% stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX) and a 5.1% stake in MEI Pharma Inc (NASDAQ:MEIP). The latter represents a decrease from the 6.8% stake Baker Bros. held in MEI a few months ago, while the fund’s position in Mirati is new. With a focus on biotech companies, it’s no surprise Julian and Felix Baker are making moves in this space.

MEI Pharma

A couple of days earlier, in a form 4, Baker Bros disclosed that its stake in Mirati Therapeutics has been purchased under the terms of an underwritten public offering, with the price amounting to $17.50 per share.

At the same time, the slice made by the fund in MEI Pharma is in contradiction with two bullish moves made by James E. Flynn‘s Deerfield Management, which reported yesterday raising its position to 1.4 million shares; and Jacob Gottlieb‘s Visium Asset Management, which earlier this month disclosed initiating a 5.4% stake in MEI Pharma.

Disclosure: none

Recommended Reading:

Moore Global’s London Arm Slices Exposure to Helphire Group

Why Warren Buffett Won’t Buy Twitter

Billionaire Eddie Lampert Cuts AutoNation Position, Still Holds a Boatload